Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARO-033

Oligonucleotide (siRNA) · developed by ARROWHEAD PHARMACEUTICALS

Phase 1 Most advanced trial

ARWR Developer

1 Registered trials

What is ARO-033?

ARO-033 is an investigational oligonucleotide studied in Age-related Macular Degeneration.

At a glance

Drug type: Oligonucleotide (siRNA)
Therapy area: Ophthalmology
Developer: ARROWHEAD PHARMACEUTICALS (ARWR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07662096	Phase 1	Age-related Macular Degeneration	Recruiting	ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Age-related Macular Degeneration

More from ARROWHEAD PHARMACEUTICALS

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-ALK7 Phase 1/2 ARO-ANG 3 Phase 2 ARO-APOC3 Phase 2 ARO-ATXN2 Phase 1 ARO-C3 Phase 1/2 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2 ARO-HBV Phase 1/2

Sources

ClinicalTrials.gov NCT07662096

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARWR page.

Follow ARWR, the company behind ARO-033

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z